AlphaValue downgrades Sandoz stock to Reduce

Published on 10/21/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock costs EUR 83.37 on October 21, 2026, while AlphaValue cut its rating. The next sales update is due on October 27, 2026.

Business update and valuation

AlphaValue downgraded Sandoz to Reduce on October 19, 2026.
First-half 2026 revenue reached USD 5.78 billion, up 9.90 percent year over year.
Sandoz stock trades at EUR 83.37 at 9:41 a.m. CEST at Lang & Schwarz on October 21, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz stock (ISIN CH1243598427) was trading at EUR 83.37 at Lang & Schwarz on October 21, 2026 at 9:41 a.m. CEST. MarketScreener reported on October 19, 2026 that AlphaValue/Baader Europe downgraded Sandoz to Reduce. The rating change puts valuation and execution back at the center of the stock story.

What does the downgrade change?

The latest analyst action comes after a strong run in the Swiss listing. Sandoz shares were quoted at CHF 76.53 in the MarketScreener report dated October 19, 2026, while the finance snapshot on October 21, 2026 showed a market capitalization of CHF 33.3 billion and a 52-week range of CHF 47.73 to CHF 77.88.

Fundamentals provide a mixed counterweight. In the first half of 2026, revenue reached USD 5.78 billion, up 9.90 percent from the first half of 2025, while net income fell to USD 109.0 million and the profit margin declined to 1.90 percent. Simply Wall St said revenue exceeded analyst estimates by 2.20 percent, but earnings per share missed estimates by 79.00 percent. That split explains why revenue growth alone has not settled the valuation debate.

Which dates matter next?

VZ reported that Sandoz had reiterated its fiscal 2026 outlook in a pre-close brief published October 1, 2026. The company expects constant-currency net sales growth in the mid-to-high single-digit range and core EBITDA margin expansion of about 100 basis points. The next sales update is scheduled for October 27, 2026, followed by a results call on October 28, 2026.

Stock price and investor view

The key tension is visible in the numbers: first-half revenue growth was 9.90 percent, but net income dropped to USD 109.0 million and the margin fell to 1.90 percent. Sandoz develops, manufactures and markets generic medicines and biosimilars, with the business split between Generics and Biosimilars and a workforce of 20,000.

Sandoz was trading at EUR 83.37 at Lang & Schwarz on October 21, 2026 at 9:41 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.